Loading clinical trials...
Loading clinical trials...
A Prospective, Randomized, Double-blind Parallel-arm, Placebo-controlled Study to Assess the Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® (Ulipristal Acetate 30 mg) or Placebo.
Conditions
Interventions
Ulipristal Acetate (UPA) + ethinylestradiol/levonorgestrel (Microgynon)
placebo + ethinylestradiol/levonorgestrel
Locations
3
Netherlands
Dinox
Groningen, Netherlands
Karolinska University Hospital Solna
Stockholm, Sweden
Chalmers Sexual Health Clinic
Edinburgh, Scotland, United Kingdom
Start Date
March 1, 2012
Primary Completion Date
August 1, 2012
Completion Date
August 1, 2012
Last Updated
June 13, 2013
NCT06162611
NCT03614494
NCT02078414
NCT03395756
NCT04172584
NCT01569737
Lead Sponsor
HRA Pharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions